메뉴 건너뛰기




Volumn 3, Issue 12, 2015, Pages 930-931

Understanding EMPA-REG OUTCOME

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; EMPAGLIFLOZIN; GLITAZONE DERIVATIVE; METFORMIN; PLACEBO; ROSIGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

EID: 84947940944     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00427-1     Document Type: Letter
Times cited : (13)

References (6)
  • 1
    • 0035133097 scopus 로고    scopus 로고
    • Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy
    • Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001, 24:5-10.
    • (2001) Diabetes Care , vol.24 , pp. 5-10
    • Poirier, P.1    Bogaty, P.2    Garneau, C.3    Marois, L.4    Dumesnil, J.G.5
  • 2
    • 0033951540 scopus 로고    scopus 로고
    • Impact of left ventricular diastolic dysfunction on maximal treadmill performance in normotensive subjects with well-controlled type 2 diabetes mellitus
    • Poirier P, Garneau C, Bogaty P, et al. Impact of left ventricular diastolic dysfunction on maximal treadmill performance in normotensive subjects with well-controlled type 2 diabetes mellitus. Am J Cardiol 2000, 85:473-477.
    • (2000) Am J Cardiol , vol.85 , pp. 473-477
    • Poirier, P.1    Garneau, C.2    Bogaty, P.3
  • 3
    • 77950507168 scopus 로고    scopus 로고
    • Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
    • Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010, 31:824-831.
    • (2010) Eur Heart J , vol.31 , pp. 824-831
    • Komajda, M.1    McMurray, J.J.2    Beck-Nielsen, H.3
  • 4
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • published online Sept 17.
    • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015, published online Sept 17. 10.1056/NEJMoa1504720.
    • (2015) N Engl J Med
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 5
    • 84944901432 scopus 로고    scopus 로고
    • Getting to the heart of the matter in type 2 diabetes
    • The Lancet Diabetes & Endocrinology
    • Getting to the heart of the matter in type 2 diabetes. Lancet Diabetes Endocrinol 2015, 3:827. The Lancet Diabetes & Endocrinology.
    • (2015) Lancet Diabetes Endocrinol , vol.3 , pp. 827
  • 6
    • 33748508810 scopus 로고    scopus 로고
    • Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes
    • Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006, 49:2256-2262.
    • (2006) Diabetologia , vol.49 , pp. 2256-2262
    • Tarnow, L.1    Gall, M.A.2    Hansen, B.V.3    Hovind, P.4    Parving, H.H.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.